AzTrials
AzTrials

PANCREATIC CANCERexpect fnaNCT01717196

Diagnostic Accuracy of FNA: is Aspiration- Related?

A study testing different volume aspiration in people with PANCREATIC CANCER, run by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

BACKGROUND: EUS-FNA has a central role in the diagnostic algorithm of solid pancreatic masses. Different needle diameters and the use of stylet are not associated with differences in terms of diagnostic yield for malignancy. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
PANCREATIC CANCER
What is being tested?
different volume aspiration
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteItaly
Study dates
Oct 2012to Oct 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosed or suspected solid pancreatic lesions according to imaging (CT-scan or/and MRI);
  • no contraindications for FNA (see exclusion criteria).

Who cannot join

  • age < 18 years;
  • cystic pancreatic lesions;
  • history of previous gastrectomy;
  • patients hemodynamically unstable or with severe coagulopathy (international normalized ratio [INR] > 1.5 or platelet count < 60.000 cells/cubic millimetre [cmm3]);
  • patients unable to suspend anticoagulant therapy;
  • pregnancy;
  • inability to give informed consent;
  • refusal to participate to the study.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • ISMETT

    Palermo, 90100

Other trials in Italy

About this study

Official title: Diagnostic Accuracy of FNA (Fine Needle Aspiration) on Solid Pancreatic Lesions: is Aspiration- Related?

BACKGROUND: EUS-FNA has a central role in the diagnostic algorithm of solid pancreatic masses. Different needle diameters and the use of stylet are not associated with differences in terms of diagnostic yield for malignancy. Preliminary studies showed that using suction (10ml) is associated with a higher sensitivity for cancer diagnosis. We aim to compare EUS-FNA in the same solid pancreatic mass performed with the 22 gauge needle with different aspiration volumes (10, 20, 0ml), looking for adequacy, diagnostic accuracy and complications.

METHODS: Prospective clinical study at four referral Centers: ISMETT Palermo; Bellaria-Maggiore, Bologna; Civico-A.R.N.A.S, Palermo; Humanitas-IRCCS, Rozzano. EUS was performed by five experienced echo-endoscopist. The needle system was in all cases the 22 gauge EUS-FNA(Expect). We performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system. For each pass tissue samples were smeared into slides for ROSE(Rapid-On-Site-Evaluation); after smearing sample into the slides, the material was fixed in formalin for cyto-histological evaluation. The cyto-pathologist was always blinded as to which aspiration was used for which specimen. After EUS-FNA the patients were monitored for at least six hour to detect immediately post-procedural complication and were followed up during the 30 days post-procedure in order to detect late complications.

Read the detailed description

Background

EUS-FNA has a central role in the diagnostic algorithm of solid pancreatic masses [ASGE Practice Committee] with high sensitivity and specificity (75-92% - 82-100%), [1-2-3] and low complication rate (1-2%) [4-5-6]. In the clinical setting of solid pancreatic mass a histological diagnosis appears highly relevant both for differential diagnosis (adenocarcinoma, lymphoma or neuroendocrine tumour) and for optimal therapeutic decision. For the cythopathologic diagnosis of pancreatic cancer, sensitivity increased with the operator's experience and reached 80% after 20 to 30 EUS-FNA. Furthermore it well demonstrated that on-site cytopathology interpretation during the procedure increase the diagnostic yield of EUS-FNA [7-8]. ROSE (Rapid On -Site Evaluation) may be useful to guide the number of FNA passes, learn which parts of the lesion may be targeted for increased diagnostic yield, and correct technical errors (e. g. bloody or paucicellular material) [9, 10]. The diagnostic yield of EUS-guided biopsies depends on size, location and characteristics of target tissues as well as on technical and procedural factors (type of needle, biopsy technique and material processing) [11-20].

Expertise and training of endosonographer and interaction with the cytopathologist have also an important role [7-14-15]. Up to now three different sizes of needle are available for collecting cytological material: 25 - 22 and 19 gauge with an aspiration volume syringe of 10ml. Most of the studies on EUS-FNA have been conducted using 22G needles. Data on thinner (25G) or larger (19G) needles are limited. A number of recent studies, including two RCTs, compared results obtained with needles of various diameters. All these studies were performed in the setting of pancreatic masses [18-20]. Although thinner needles provide less cellular material than do larger needles, the specimens from the former are less contaminated by blood, and thus easier to interpret. In addition, thinner needles may be easier to use because of greater flexibility, particularly for locations requiring important scope bending [18, 19]. An RCT in 131 patients found no significant differences between 22G and 25G needles in terms of diagnostic yield for malignancy [17]. Finally another RCT compared EUS-FNA without ROSE using 19G or 22G needles in 117 patients [18] showed a similar diagnostic accuracy for both needles.

If the diameter of the needle used does not appear to affect the diagnostic accuracy of FNA on solid pancreatic lesions, preliminary studies show that using suction during EUS FNA of solid masses is associated with a significantly higher sensitivity for cancer diagnosis (86% vs. 67%; P=0.05) [20]. A pilot trial suggested that applying continuous high pressure suction (using a balloon inflation device) allowed retrieval of tissue samples for histopathological examination in most cases [21].

A new needle Expect by Boston Scientific are available with an aspiration syringe with variable volume of 5-10-15-20cc. No studies were performed comparing the diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.

Aims

The aims of our prospective study are to compare EUS-FNA in the same solid pancreatic mass performed with the 22 gauge needle with aspiration volume syringe of 10ml, 20ml and without aspiration, looking for: sample adequacy, diagnostic accuracy, complications.

Methods

Patients This was a prospective clinical study at four referral center for EUS: ISMETT/UPMC (Mediterranean Institute for Transplantation and Advanced Specialized Therapies/University of Pittsburgh Medical Center in Italy), Palermo; AUSL Bologna, Bellaria-Maggiore Hospital; Civico-A.R.N.A.S. Hospital, Palermo; Humanitas IRCCS, Rozzano, Milano. We planned to collect at least 100 cases in 3 months. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) as reflected in a priori approval by the institution's human research committees.

The inclusion criteria for the study were: diagnosed or suspected solid pancreatic lesions according to imaging (CT-scan or/and MRI); no contraindications for FNA (see exclusion criteria). The exclusion criteria were: age < 18 years; cystic pancreatic lesions; history of previous gastrectomy; patients hemodynamically unstable or with severe coagulopathy (international normalized ratio [INR] > 1.5 or platelet count < 60.000 cells/cubic millimetre [cmm3]); patients unable to suspend anticoagulant therapy; pregnancy; inability to give informed consent; refusal to participate to the study.

Data on comorbidity and chronic treatment were recorded as well as data on possible complications related to the procedure. Patients undergoing anticoagulant or antiaggregant therapy for noncritical problems discontinued the treatment at least 5 days before the endoscopic procedure or until INR normalization, starting low dose heparin. Written informed consent was obtained from all patients for the procedures performed. All procedures were performed under conscious sedation with meperidine ± midazolam or deep sedation with propofol according to each center guideline and patient clinical condition.

Procedure Endoscopic ultrasonography was performed using a linear echo-endoscope by five experienced echo-endoscopist with a current case volume of at list 500 per year (200 FNA). The standard technique for FNA was adopted: the needle is advanced under real-time EUS guidance into the target lesion by using a quick, strong thrust of the handle. The stylet is completely withdrawn and a syringe attached to the end of the needle device. Once inside the lesion, after applying negative pressure suction by opening the lock device of the syringe, the needle is moved back and forth 15 times under EUS guidance. The suction syringe is then released, the needle withdrawn into the catheter, and the whole system removed from the echoendoscope.

The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.

Technical success was defined as puncturing the target tissue properly without technical difficulties (inability of the needle to exit from the channel of the scope) or mechanical rupture and obtaining some visible tissue specimens or fragments with each puncture.

Tissue samples was immediately smeared into slides after each puncture, fixed and all the prepared slides will be viewed by experienced pathologists for ROSE (Rapid On Site Evaluation). For each pass, after smearing sample into the slides, the material was fixed in formalin for cyto histological evaluation. The cytopathologist was always blinded as to which aspiration was used for which specimen.

The cases will be stratified into 4 diagnostic categories applied for ROSE and for histological evaluation:

  1. Positive for malignancy, b) Suspicious for malignancy, c) Negative for malignancy, d) Non diagnostic.

For each aspiration two fundamental parameters will be evaluated on slides and formalin fixed sample: sample adequacy intended as overall cellularity (including normal, neoplastic, non-epithelial cells) and diagnostic accuracy.

Post-procedural follow-up After EUS-FNA the patients were monitored for at least six hour to detect immediately post-procedural complication and were followed up with a scheduled protocol during the 30 days post-procedure in order to evaluate clinical status, blood chemistry, and to detect late complications. All patients were followed up for at least 1 month. All adverse events were evaluated and related or not to the procedure. All data were recorded electronically on excel database for the final analysis.

STATISTICAL ANALYSIS Data were analyzed using the SPSS 15 software package (SPSS Inc., Chicago, Illinois, USA). Continuous variables were summarized as means ± SD, or range, when appropriate. Categorical variables were summarized as frequency and percentage. For comparison of qualitative variables, a chi-squared test was calculated. For comparison of quantitative variables, Students t test was used. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy for each arm was investigated. Differences were considered significant at a P value of <0.05 (two-sided).

Being tested
different volume aspiration
Keywords
sample adequacy, diagnostic accuracy, complications
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • different volume aspirationOther

    comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.

Study groups in NCT01717196
Study groupRoleWhat they receive
DIFFERENT VOLUME ASPIRATION BIOPSYExperimentalThe needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
Receives: Other: different volume aspiration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. sample adequacy

    Tissue samples was immediately smeared into slides after each puncture, fixed and all the prepared slides will be viewed by experienced pathologists for ROSE (Rapid On Site Evaluation). For each pass, after smearing sample into the slides, the material was fixed in formalin for cyto histological evaluation. The cytopathologist was always blinded as to which aspiration was used for which specimen.

    Measured: 20min

Secondary outcomes (1)
  1. diagnostic accuracy

    For each pass, after smearing sample into the slides, the material was fixed in formalin for cyto histological evaluation. The cytopathologist was always blinded as to which aspiration was used for which specimen.

    The cases will be stratified into 4 diagnostic categories applied for ROSE and for histological evaluation:

    1. Positive for malignancy, b) Suspicious for malignancy, c) Negative for malignancy, d) Non diagnostic.

    Measured: 5 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2012 (estimated)
  2. Study startOct 2012
  3. Primary completionOct 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
Single blind
Who is masked
Investigator
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01717196
Sponsor's protocol ID
EX0001
Acronym
expect fna
Status last verified
Oct 2012
First submitted
22 Oct 2012
Last updated
30 Oct 2012
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing different volume aspiration in people with PANCREATIC CANCER, run by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

sample adequacy (time frame: 20min). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in